Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Goodwill

The premium paid for acquisitions above the fair value of the identifiable net assets acquired.

Aura Biosciences, Inc.NASDAQ: AURA

Goodwill · Q1 FY2026 · quarter ended Mar 2026

Goodwill remains negative

Q1 FY2026 goodwill was $0, compared with $0 a year earlier.

Context

  • Goodwill amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Goodwill increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Goodwill past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Goodwill history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Goodwill vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so goodwill is compared through growth and share of total assets rather than absolute size.
  • Goodwill amounts to 0.0% of total assets for AURA, versus a peer median of 0.0%.
AURA Competitors
Goodwill for AURA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AURAAura Biosciences, Inc.Mar 2026$0 USD——0.0%
IMNMImmunome, Inc.Sep 2026$0 USD——0.0%
AKTSAktis Oncology, Inc.Mar 2026$0 USD——0.0%
OCSOculis Holding AGMar 2026CHF 0 CHF——0.0%
OCGNOcugen, Inc.Mar 2026$0 USD——0.0%
BCYCBicycle Therapeutics plcMar 2026$0 USD——0.0%
WHWKWhitehawk Therapeutics IncMar 2026$0 USD——0.0%
MGNXMacroGenics, Inc.Mar 2026$0 USD——0.0%
OTLKOutlook Therapeutics, Inc.Mar 2026$0 USD——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$0 USD——0.0%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding AURA) ———0.0%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents149.06M121.58M41.06M31.69M59.52M
Short-term Investments067.23M185.09M119.4M84.73M
Net Receivables00000
Inventory00000
Other Current Assets89K5.72M3.83M1.83M1.18M
Total Current Assets153.7M196.7M231.79M160.62M149.74M
Property, Plant & Equipment (Net)6.2M26.04M22M20.59M18.45M
Goodwill00000
Intangible Assets00000
Long-term Investments0768K000
Tax Assets00000
Other Non-current Assets125K423K1.28M1.29M1.24M
Total Non-current Assets6.33M27.23M23.28M21.88M19.69M
Total Assets160.03M223.94M255.08M182.5M169.43M
Account Payables2.4M2.92M1.79M2.3M1.55M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.65M3.03M935K618K6.25M
Total Current Liabilities7.36M10.46M12.36M14.91M18.38M
Long-term Debt000014.13M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities360K17.9M16.87M15.62M14.13M
Total Liabilities7.72M28.35M29.23M30.53M32.52M
Common Stock00000
Retained Earnings(152.14M)(210.9M)(287.31M)(374.23M)(480.42M)
Accumulated OCI0(72K)539K263K(102K)
Other Stockholders Equity001K00
Minority Interest00000
Total Equity152.32M195.58M225.85M151.97M136.91M
Total Debt975K20.86M19.56M18.77M17.38M
Net Debt(148.09M)(100.72M)(21.51M)(12.92M)(42.14M)

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.